Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.56 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.56 |
| ▸ | CTSD | P07339 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29373148 | 0.88 | BACE1 (0.60) | BACE1BACE2CTSDOPRD1 | |
| SCHEMBL676220 | 0.85 | BACE1 (0.48) | BACE1BACE2OPRD1 | |
| SCHEMBL30455442 | 0.84 | BACE1 (0.64) | BACE1BACE2CTSD | |
| SCHEMBL29375830 | 0.83 | BACE1 (0.59) | BACE1BACE2CTSDOPRD1 | |
| SCHEMBL31510101 | 0.82 | BACE1 (0.67) | BACE1BACE2CTSDOPRD1 | |
| SCHEMBL30124150 | 0.82 | NPY4R (0.58) | BACE1BACE2OPRD1 | |
| SCHEMBL2159156 | 0.82 | ENPEP (0.52) | OPRD1 | |
| SCHEMBL1274597 | 0.81 | OPRM1 (0.57) | BACE1BACE2OPRD1 | |
| SCHEMBL30513621 | 0.81 | BACE1 (0.66) | BACE1BACE2CTSDOPRD1 | |
| SCHEMBL38662087 | 0.81 | BACE1 (0.56) | BACE1BACE2CTSDOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | BACE1 4076/4885BACE2 2622/4885CTSD 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.